Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 6;17(1):15.
doi: 10.1186/s13062-022-00322-0.

The current state of molecular profiling in gastrointestinal malignancies

Reetu Mukherji  1   2 , Chao Yin  1   2 , Rumaisa Hameed  1   2 , Ali Z Alqahtani  1   2 , Monika Kulasekaran  1   2 , Aiwu R He  1   2 , Benjamin A Weinberg  1   2 , John L Marshall  1   2 , Marion L Hartley  1 , Marcus S Noel  3   4
Affiliations
Review

The current state of molecular profiling in gastrointestinal malignancies

Reetu Mukherji et al. Biol Direct. .

Abstract

This is a review of the current state of molecular profiling in gastrointestinal (GI) cancers and what to expect from this evolving field in the future. Individualized medicine is moving from broad panel testing of numerous genes or gene products in tumor biopsy samples, identifying biomarkers of prognosis and treatment response, to relatively noninvasive liquid biopsy assays, building on what we have learned in our tumor analysis and growing into its own evolving predictive and prognostic subspecialty. Hence, the field of GI precision oncology is exploding, and this review endeavors to summarize where we are now in preparation for the journey ahead.

Keywords: Biomarker; CTC; Colorectal cancer; Gastroesophageal cancer; Gastrointestinal, GI; Hepatobiliary cancer; Liquid biopsy; Molecular profiling; Next-generation sequencing, NGS; Pancreatic cancer; ctDNA.

PubMed Disclaimer

Conflict of interest statement

CY, None; RM, None; RH, None; AZA, None; MK, None; ARH, Grant or research support-Merck (Merck Sharp & Dohme a subsidiary of Merck & Co, Inc.), grant or research support-Genentech, Inc., Speakers Bureau-Eisai, Speakers Bureau-BMS; BAW, Personal fees from Taiho, Lilly, Sirtex, Bayer, and Daiichi Sankyo/AstraZeneca, and grants from Ipsen outside the submitted work; JLM, Honoraria—Pfizer, Inc., and Daiichi Sankyo, Inc. Advisor—Bayer Corporation, and Taiho Oncology; MLH, None; MSN: Support from Ipsen outside the submitted work.

Figures

Fig. 1
Fig. 1
Predictive biomarkers in GI malignancies
Fig. 2
Fig. 2
Potential ctDNA applications
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Shu Y, et al. Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Sci Rep. 2017;7:583. doi: 10.1038/s41598-017-00520-1. - DOI - PMC - PubMed
    1. Dasari A, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020;17:757–770. doi: 10.1038/s41571-020-0392-0. - DOI - PMC - PubMed
    1. Parikh AR, et al. Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers. Clin Cancer Res. 2020;26:1877–1885. doi: 10.1158/1078-0432.CCR-19-3467. - DOI - PMC - PubMed
    1. Moroni M, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279–286. doi: 10.1016/S1470-2045(05)70102-9. - DOI - PubMed
    1. Lievre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374–379. doi: 10.1200/JCO.2007.12.5906. - DOI - PubMed

Substances

LinkOut - more resources